As the official podcast of the American College of Rheumatology, ACR on Air dives into topics such as the latest research on rheumatic disease, solutions for addressing practice management issues, legislative policies impacting patient care, and more. Tune in each month for engaging interviews and commentary with leading rheumatology professionals that is sure to empower listeners to excel in their specialty.
Jonathan Hausmann, MD, is a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center. He is also an Assistant Professor of Medicine at Harvard Medical School. His research interests include autoinflammatory diseases, health technology, and medical education. Connect with Dr. Hausmann on Twitter (@hausmannMD).
New episodes will be available twice a month on Tuesdays. Browse previous episodes in the ACR on Air archive.
During the Great Debate at ACR Convergence 2020, the question: “Should JAK inhibitors be started before TNF inhibitors in people with rheumatoid arthritis who failed methotrexate?” was asked. However, in 2021, results from the oral surveillance trial showed an increased risk of major adverse cardiovascular events in cancers among patients with rheumatoid arthritis taking tofacitinib as compared to those on TNF inhibitors. These findings led to the FDA updating their black box warning on JAK inhibitors. In this episode, Great Debate speaker, Vibeke Strand, MD, MACR, FACP, joins us to speak on her position on JAK inhibitors given these new results and shed some more light on the subject.
Speaker Vibeke Strand, MD, MACR, FACP - Vibeke Strand, MD, MACR, FACP, has served as an adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine since 1993, previously at UCSF. Since 1991, she has led a consulting practice offering clinical research and regulatory strategy expertise to pharmaceutical and biotech companies for development of new therapies in rheumatic diseases. She has participated in the development of all the approved biologic agents and targeted synthetic DMARDs in RA, as well as new therapies for PsA, SpA, SLE, vasculitis, gout, biosimilars and symptomatic therapies in OA.
She was previously a clinical investigator in subspecialty practice in San Francisco for 6 years, and senior director of clinical research at 3 pharmaceutical / biotech companies for 6 years.
She has authored more than 490 publications, is a Fellow of the American College of Physicians (1982), Master of the American College of Rheumatology (2015) and member of the Cosmos Club (1994). She has been a member of the Executive Committee of the international Outcomes in Rheumatology Clinical Trials (OMERACT) consensus conferences since its inception in 1992; Steering Committee of Group for Research and Assessment of PsO and PsA (GRAPPA) 2003, and Board of International Dermatology Outcome Measures (IDEOM) 2019.
Don’t forget to like, share, and subscribe!
Submit Show Feedback
Clinical expert of spondyloarthritis, Maureen Dubreuil, MD, MSc, joins us in this episode of ACR on Air to discuss treating spondyloarthritis. Dr. Dubreuil discusses how she evaluates and treats patients with this specific condition and shares tips and insights into how to diagnose and manage this disease.
Maureen Dubreuil, MD, MSc - Maureen Dubreuil, MD, MSc, is a rheumatologist in Boston, specializing in spondyloarthritis at Boston University School of Medicine, where her research focuses on comorbidities and pharmacoepidemiology of spondyloarthritis. She serves as Education Chair and Board Member for the Spondyloarthritis Research and Treatment Network (SPARTAN), is a Medical Advisor for the Spondylitis Association of America, a member of the Assessment of Spondyloarthritis International Society (ASAS), and a site investigator for the international CLASSIC study and the PULSAR spondyloarthritis registry. In 2013, she was awarded the Arthritis Foundation Clinical to Research Transition Award and 2016 she began work on a K23-funded project to study patient preferences, and the cost-effectiveness of treatment modalities for spondyloarthritis, to inform both clinical care and policy decisions.
This week’s episode is another installment of our popular Hot Topics series, where we discuss “must read” studies recently published in one of ACR’s three peer-reviewed journals. Joining us is Vicki Shanmugam, MBBS, MRCP, CCD. Dr. Shanmugam is not only our guest in this episode, but also the host of a new ACR podcast series, “ACR Journals on Air,” scheduled to launch later this summer. In this episode, we’ll hear what we can expect from the new podcast, and we’ll talk about some of her recent favorite studies in the ACR’s journals.
Vicki Shanmugam, MBBS, MRCP, CCD - Vicki Shanmugam, MBBS, MRCP, CCD, has clinical expertise caring for patients with autoimmune diseases, vasculitis, and chronic wounds. She has led several research studies investigating scleroderma, hidradenitis suppurativa, and the interplay of the host immune response and the microbiome in chronic wounds. Dr. Shanmugam is a frequently invited speaker at professional meetings. Her work in wound healing, hidradenitis, and scleroderma has been published in high-impact peer-reviewed journals, such as Arthritis Care & Research, Current Opinion in Rheumatology, International Wound Journal, and Clinical Rheumatology.
In this week’s episode, we discuss the ACR’s 2022 Guideline Summary for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases with lead author Anne Bass, MD, Attending Physician in the Division of Rheumatology at Hospital for Special Surgery, and a Professor of Clinical Medicine at Weill Cornell Medicine. During our conversation we discussed the rationale for this guideline, the impact of drugs like rituximab and methotrexate on vaccination responses, medication management at the time of live-attenuated vaccines, and how this guideline may help navigate insurance company vaccine approvals and much, much more.
Anne Bass, MD - Anne Bass, MD, is an Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and a Professor of Clinical Medicine at Weill Cornell Medicine. She specializes in the treatment of patients with autoimmune side effects of cancer immunotherapy, and sees patients with inflammatory arthritis, vasculitis, and other autoimmune conditions. Dr. Bass co-directs the HSS Checkpoint inhibitor associated arthritis registry and is doing translational research to better understand this condition.
Today we’re talking about implicit bias. What it is, how it permeates our lives, how it can negatively impact our workforce, and its impact on clinical research and patient care. Most importantly, we discuss what we can do about our implicit biases to prevent them from causing damage.
Arin N. Reeves, PhD - Arin N. Reeves, PhD, is a leading researcher, author, and advisor in the fields of leadership and inclusion. Dr. Reeves studied business at DePaul University’s College of Commerce, attended law school at the University of Southern California and received her PhD in Sociology from Northwestern University. Dr. Reeves is a best-selling author of four books – In Charge (2022), Smarter Than A Lie (2019), One
Size Never Fits All (2014), and The Next IQ (2012). Dr. Reeves has designed and led several comprehensive research projects on leadership and inclusion in various topics related to diversity, inclusion, and equity. Before Nextions, Dr. Reeves practiced law for several years and served as an Adjunct Professor at Northwestern University, where she taught classes on law and society.
Related Research Links:
ACR on Air is also available in the following podcast listening platforms. Choose your preferred mobile application to subscribe, and you will be able to listen to ACR on Air on the go.
We'd love to hear from our listeners. Tell us how we are doing.